A Phase 3 interventional study of ezetimibe (+) simvastatin and Comparator: atorvastatin calcium in Hypercholesterolemia and Metabolic Syndrome, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 5th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 18th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 16 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,143 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 11th largest by enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2007, is one of 58 in phase 3, and was the 31st registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 6-week clinical trial in patients with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease to study the effects of ezetimibe/simvastatin and atorvastatin on lipids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Arm 1: drug + comparator + Placebo
Drug: ezetimibe (+) simvastatin · Drug: Comparator: atorvastatin calcium · Drug: Comparator: Placebo (unspecified)
Arm 2: drug + comparator + Placebo
Drug: ezetimibe (+) simvastatin · Drug: Comparator: atorvastatin calcium · Drug: Comparator: Placebo (unspecified)
Arm 3: drug + comparator + Placebo
Drug: ezetimibe (+) simvastatin · Drug: Comparator: atorvastatin calcium · Drug: Comparator: Placebo (unspecified)
Arm 4: drug + comparator + Placebo
Drug: ezetimibe (+) simvastatin · Drug: Comparator: atorvastatin calcium · Drug: Comparator: Placebo (unspecified)
Arm 5: drug + comparator + Placebo
Drug: ezetimibe (+) simvastatin · Drug: Comparator: atorvastatin calcium · Drug: Comparator: Placebo (unspecified)
Drug pages: Ezetimibe · Simvastatin
Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
Also known as: MK0653A, Vytorin®
Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets. Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
Also known as: Lipitor ®
Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets. ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets. Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6
Time frame: Baseline and 6 weeks
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD)
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD)
Time frame: Baseline and 6 Weeks
Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6
Time frame: Baseline and 6 Weeks
Phase III First Patient In 06-Feb-2007:; Last Patient Last Visit 16-Jul-2008 110 centers worldwide (International, 12 countries) Eligible patients include drug-naïve patients or patients rendered naïve with the appropriate prior washout at moderately high or high risk for coronary heart disease.
| Milestone | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Started | 229 | 229 | 229 | 228 | 228 |
| Completed | 220 | 222 | 220 | 216 | 218 |
| Not completed | 9 | 7 | 9 | 12 | 10 |
| Withdrew: Adverse event | 3 | 4 | 4 | 2 | 6 |
| Withdrew: Lost to follow-up | 6 | 1 | 2 | 3 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 3 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Lack of eligibility | 0 | 0 | 0 | 0 | 1 |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 | -36.5 (-38.9 to -34.0) | -49.6 (-52.0 to -47.2) | -39.4 (-41.8 to -36.9) | -53.9 (-56.4 to -51.5) | -46.0 (-48.4 to -43.6) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6 | -26.5 (-28.2 to -24.7) | -33.7 (-35.4 to -31.9) | -28.3 (-30.1 to -26.6) | -37.3 (-39.0 to -35.5) | -32.8 (-34.6 to -31.1) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6 | -21.7 (-25.0 to -17.9) | -23.3 (-26.9 to -18.2) | -27.5 (-30.8 to -22.4) | -29.5 (-32.5 to -25.0) | -30.0 (-34.2 to -26.5) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6 | 3.4 (1.5 to 5.3) | 6.8 (4.9 to 8.7) | 5.6 (3.7 to 7.5) | 8.8 (6.9 to 10.7) | 4.9 (3.0 to 6.8) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6 | -33.5 (-35.6 to -31.3) | -43.8 (-45.9 to -41.7) | -36.5 (-38.6 to -34.4) | -48.3 (-50.5 to -46.2) | -41.4 (-43.6 to -39.3) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6 | -17.7 (-21.4 to -14.0) | -18.3 (-22.0 to -14.7) | -21.6 (-25.3 to -17.8) | -23.4 (-27.1 to -19.7) | -22.7 (-26.4 to -19.0) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6 | -27.9 (-29.9 to -25.9) | -37.2 (-39.2 to -35.3) | -31.9 (-33.9 to -29.9) | -41.1 (-43.1 to -39.1) | -35.8 (-37.8 to -33.8) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6 | 0.8 (-1.0 to 2.5) | 3.2 (1.5 to 4.9) | 1.0 (-0.7 to 2.7) | 3.0 (1.3 to 4.7) | 1.4 (-0.3 to 3.1) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6 | -28.1 (-30.1 to -26.0) | -36.9 (-38.9 to -34.8) | -31.5 (-33.6 to -29.5) | -41.2 (-43.2 to -39.1) | -35.3 (-37.3 to -33.2) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6 | -37.8 (-40.3 to -35.2) | -51.8 (-54.3 to -49.3) | -42.1 (-44.7 to -39.6) | -56.6 (-59.2 to -54.1) | -48.2 (-50.7 to -45.6) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6 | -27.4 (-29.6 to -25.2) | -38.4 (-40.6 to -36.2) | -32.0 (-34.2 to -29.8) | -41.9 (-44.1 to -39.7) | -36.2 (-38.4 to -34.0) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6 | -34.7 (-37.2 to -32.2) | -46.2 (-48.6 to -43.7) | -39.2 (-41.7 to -36.7) | -51.2 (-53.7 to -48.7) | -43.5 (-46.0 to -41.0) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD) | -37.1 (-41.4 to -32.7) | -48.7 (-52.8 to -44.6) | -36.9 (-41.5 to -32.4) | -56.1 (-60.6 to -51.7) | -45.8 (-50.2 to -41.5) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD) | -36.3 (-39.1 to -33.5) | -50.1 (-52.9 to -47.2) | -40.3 (-43.1 to -37.6) | -53.2 (-55.9 to -50.4) | -46.1 (-48.9 to -43.3) |
| Percent Change | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6 | -16.8 (-21.7 to -10.6) | -17.2 (-24.1 to -12.5) | -22.4 (-26.1 to -14.6) | -27.6 (-33.3 to -21.4) | -30.0 (-33.3 to -25.0) |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorva 10 mg | — | — | — |
| EZ/Simva 10 mg/20 mg | — | — | — |
| Atorva 20mg | — | — | — |
| EZ/Simva 10 mg/40 mg | — | — | — |
| Atorva 40 mg | — | — | — |
| Event | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Atrioventricular Block Second DegreeCardiac disorders | 0/228 | 0/226 | 0/226 | 1/224 | 0/224 |
| TachyarrhythmiaCardiac disorders | 0/228 | 0/226 | 0/226 | 0/224 | 1/224 |
| CholestasisHepatobiliary disorders | 0/228 | 0/226 | 0/226 | 0/224 | 1/224 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/228 | 0/226 | 0/226 | 0/224 | 1/224 |
| Cerebrovascular AccidentNervous system disorders | 0/228 | 0/226 | 0/226 | 0/224 | 1/224 |
| Sick Sinus SyndromeCardiac disorders | 0/228 | 0/226 | 1/226 | 0/224 | 0/224 |
| Urinary Tract InfectionInfections and infestations | 0/228 | 0/226 | 1/226 | 0/224 | 0/224 |
| Acute Myocardial InfarctionCardiac disorders | 1/228 | 0/226 | 0/226 | 0/224 | 0/224 |
| Atrial FibrillationCardiac disorders | 1/228 | 0/226 | 0/226 | 0/224 | 0/224 |
| HeadacheNervous system disorders | 1/228 | 0/226 | 0/226 | 0/224 | 0/224 |
| Event | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg |
|---|---|---|---|---|---|
| Any Musculoskeletal And Connective Tissue DisordersMusculoskeletal and connective tissue disorders | 8/228 | 7/226 | 9/226 | 5/224 | 7/224 |
| Any Gastrointestinal DisordersGastrointestinal disorders | 7/228 | 6/226 | 7/226 | 4/224 | 2/224 |
| DiarrhoeaGastrointestinal disorders | 5/228 | 1/226 | 3/226 | 1/224 | 1/224 |
| Any Nervous System DisordersNervous system disorders | 4/228 | 2/226 | 4/226 | 3/224 | 2/224 |
| HeadacheNervous system disorders | 4/228 | 0/226 | 4/226 | 0/224 | 2/224 |
| Back PainMusculoskeletal and connective tissue disorders | 0/228 | 2/226 | 0/226 | 3/224 | 2/224 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/228 | 2/226 | 3/226 | 0/224 | 3/224 |
| DizzinessNervous system disorders | 0/228 | 2/226 | 0/226 | 3/224 | 0/224 |
| Abdominal TendernessGastrointestinal disorders | 1/228 | 2/226 | 3/226 | 1/224 | 0/224 |
| NauseaGastrointestinal disorders | 1/228 | 3/226 | 1/226 | 2/224 | 1/224 |
| Age, Continuous(years) | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 59.7 (31 to 79) | 59.7 (32 to 78) | 58.2 (33 to 78) | 59.5 (28 to 80) | 58.4 (28 to 79) | 59.1 (28 to 80) |
| Sex: Female, Male(Participants) | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg | Total |
|---|---|---|---|---|---|---|
| Female | 97 | 87 | 106 | 104 | 104 | 498 |
| Male | 132 | 142 | 123 | 124 | 124 | 645 |
| Race/Ethnicity, Customized(participants) | Atorva 10 mg | EZ/Simva 10 mg/20 mg | Atorva 20mg | EZ/Simva 10 mg/40 mg | Atorva 40 mg | Total |
|---|---|---|---|---|---|---|
| Asian | 17 | 15 | 15 | 18 | 21 | 86 |
| Black | 13 | 18 | 18 | 12 | 14 | 75 |
| Other | 27 | 27 | 19 | 27 | 26 | 126 |
| White | 172 | 169 | 177 | 171 | 167 | 856 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Jan 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin